SARS-CoV-2 is the virus that causes the COVID-19 disease (Coronovirus Disease 2019). MBLI understands the urgent need to have better understanding and characterization of this disease. They are continuing to develop and launch new products for the research community as fast as they can.
MBLI offers SMITEST for RNA extraction from various sample types. RT-PCR (reverse transcription-polymerase chain reaction) tests are commonly used to detect the SARS-CoV-2 virus. FLUOROSEARCH is an RT-PCR detection kit readily available for detecting this virus within 1.5 hours.
T-cells are activated only by interacting with processed peptides (e.g. of SARS-CoV-2) that sit in the groove of MHC Class I and II molecules. Identifying these peptides can be used (in forms of peptide-MHC tetramers) to asses vaccine-induced immunity and assist in designing potent vaccines with durable responses. COVID-19 infected cells can be recognized by T-cells only after SARS-CoV-2 peptides are processed and presented in the context of self MHCs.
Identifying these peptides have essential utilities:
- Immune monitoring: Using peptide-MHC tetramers to assess vaccine-induced immunity
- Designing potent vaccines that elicit durable responses
MBL International can assist companies and academic investigators who are actively developing coronavirus vaccines with their unique QuickSwitch™ custom tetramer platform. QuickSwitch™ is a peptide screening plug and play platform that identifies peptides that are more likely to be immunogenic and yet generates corresponding Class I and Class II MHC tetramers. This platform can identify and validate multi-epitope candidates of SARS-CoV-2 proteins that can potentially elicit for both CD4+ and CD8+ T-cell immune responses. By using MBLI’s MHC tetramer exchange QuickSwitch™ platform for peptide screening, you can identify/validate the binding of predicted peptide sequences of the COVID-19 viral proteins in most common alleles: HLA-A2, A11, A24, A3 and HLA-DR1, DR4, DR15.
View all MBL Covid-19 products here.